AVEO Pharmaceuticals, Inc. (AVEO) Lifted to Strong-Buy at BidaskClub

BidaskClub upgraded shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) from a buy rating to a strong-buy rating in a research note issued to investors on Wednesday.

Several other analysts have also recently weighed in on AVEO. Piper Jaffray Companies reissued a buy rating and set a $3.50 price objective on shares of AVEO Pharmaceuticals in a report on Thursday, August 10th. FBR & Co reissued an outperform rating and set a $3.00 price objective on shares of AVEO Pharmaceuticals in a report on Thursday, July 13th. ValuEngine cut AVEO Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, June 2nd. Finally, Zacks Investment Research raised AVEO Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, May 23rd. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $3.08.

AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 3.07 on Wednesday. The firm’s 50-day moving average is $2.66 and its 200 day moving average is $1.24. The firm’s market cap is $363.20 million. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $3.30.

COPYRIGHT VIOLATION NOTICE: This report was posted by [[site]] and is the property of of [[site]]. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at [[permalink]].

A number of hedge funds have recently made changes to their positions in the company. Fore Research & Management LP purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at $111,000. Clear Harbor Asset Management LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at $289,000. Cannell Peter B & Co. Inc. boosted its stake in shares of AVEO Pharmaceuticals by 22.9% in the second quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 20,500 shares in the last quarter. Paloma Partners Management Co purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at $184,000. Finally, UBS Oconnor LLC purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at $291,000. 51.03% of the stock is owned by hedge funds and other institutional investors.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.